ABNCoV2 cVLP based COVID-19 vaccine (AdaptVac)

N/A

Report date: 2022/09/16 20:00:52

Base Information

Drug NameABNCoV2 cVLP based COVID-19 vaccine (AdaptVac)
Drug Alias NameABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine (AdaptVac)ABNCoV2
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Severe Acute Respiratory Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAdaptVac
China Registration ClassN/A

Develop Information

Active CompaniesThe Danish Ministry Of Health (2003-0200-13)Radboud University Medical CenterRadboud University Nijmegen +[4] 
Inactive CompaniesAdaptVac
Active IndicationsCoronavirus Disease 2019 (COVID-19)Severe Acute Respiratory Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A